Novartis AG (NOVN) PT Set at CHF 78 by Deutsche Bank AG
Novartis AG (VTX:NOVN) has been given a CHF 78 price target by equities researchers at Deutsche Bank AG in a note issued to investors on Wednesday. The firm presently has a “neutral” rating on the stock.
A number of other brokerages have also recently weighed in on NOVN. Morgan Stanley set a CHF 75 target price on shares of Novartis AG and gave the stock a “sell” rating in a report on Monday, May 29th. J P Morgan Chase & Co set a CHF 70 target price on shares of Novartis AG and gave the stock a “neutral” rating in a report on Saturday, May 20th. Goldman Sachs Group, Inc. (The) set a CHF 80 target price on shares of Novartis AG and gave the stock a “neutral” rating in a report on Friday, June 2nd. HSBC Holdings plc set a CHF 85 target price on shares of Novartis AG and gave the stock a “buy” rating in a report on Wednesday. Finally, Jefferies Group LLC set a CHF 100 target price on shares of Novartis AG and gave the stock a “buy” rating in a report on Saturday, May 20th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of CHF 81.57.
Novartis AG (VTX:NOVN) traded down 0.12% during midday trading on Wednesday, hitting CHK 83.70. 6,857,714 shares of the stock were exchanged. The firm’s 50-day moving average is CHK 78.82 and its 200 day moving average is CHK 75.33. Novartis AG has a 52 week low of CHK 67.40 and a 52 week high of CHK 84.35.
TRADEMARK VIOLATION WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/06/25/novartis-ag-novn-pt-set-at-chf-78-by-deutsche-bank-ag.html.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.